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LOW EFFICACY OF AZITHROMYCIN TO TREAT CUTANEOUS LEISHMANIASIS
IN MANAUS, AM, BRAZIL
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SUMMARY
An open trial to evaluate the azithromycin efficacy in cutaneous leishmaniasis patients was carried out in Manaus (AM),
where Leishmania (Viannia) guyanensis is the main etiologic agent. Forty-one patients with skin lesions of less than 12 weeks
duration, without specific treatment for the last three months and a positive imprint to Leishmania sp. were included. From these,
31 (75.6%) were male with median age of 30.2. All of them received a daily-single oral dose of 500 mg of azithromycin for ten
days. At 25th day, 16 (39%) presented therapeutic failure and received intramuscular pentavalent antimonial, four were considered
lost, 21, that had improved or were inaltered received another ten-day series of azithromycin and were monthly followed, but nine
(21.9%) of them presented a poor clinical response and switched to intramuscular pentavalent antimonial on day 55. Of the 12
remaining cases evaluated on day 55, despite of clinical improvement, three asked for antimony therapy and 9 (21.9%) continued
the follow-up but, only three were cured on 55th, 85th and 115th days, and six did not come back for final evaluation. The intention-
treatment overall response rate was 22% and whole cure was seen in three (7.3%) of cases. Thus, azithromycin showed a low
efficacy to treat cutaneous leishmaniasis in Manaus.
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INTRODUCTION
During several decades, pentavalent antimonials have been the first
choice to treat leishmaniasis in most places where it is endemic and
other alternatives as amphotericin B and pentamidin have also been
used with good results (MARSDEN, 1985; OLLIARO & BRYCESON,
1993; HEPBURN et al., 1994). These drugs must be administered by
parenteral route, for three or four weeks, are toxic and sometimes patient
hospitalization is required (HERWALDT, 1999; LLANOS-CUENTAS
et al., 1984; ROMERO et al., 2001; ANTEZANA et al., 1992).
Attempts to find oral therapeutic options, ideally cheaper, with
good tolerance and safe are highly desirable. In the last years, some
trials using different oral medicaments with antileishmania effect were
carried out with variable results, depending on clinical picture and
leishmania sp. (JHA, 1983; GRIMALDI et al., 1989; DOGRA &
SAXENA, 1996; ALRAJHI et al., 2002). Recently, miltefosine, an
alkil fospholipid derivated cured 94% of patients with visceral
leishmaniasis in India. Similar results for cutaneous leishmaniasis in
Colombia were also reported (SUNDAR et al. 2002; SOTO et al., 2001).
Azithromycin, a macrolide antibiotic, has been used to treat several
bacterial infections, mainly those caused by intracellular microbes,
due to its good tissular concentration within phagocytes and its
prolonged half life (PETERS, 1992; NEU, 1991; GIRARD et al., 1987;
FOULDS & JOHNSON, 1993; FOULDS et al., 1990). After a single
oral dose, azithromycin showed activity against atypical mycobacteria
sp., Toxoplasma gondii, Cryptosporidium sp., and Babesia microtii,
among others (WILDFEUER et al., 1996; KOLETAR et al., 1999;
GIACOMETTI et al., 2000, PUKRITTAYAKAMEE et al., 2001;
KRAUSE et al., 2000).
In experimental model in vivo and in vitro, using Leishmania major
promastigotes in an acellular culture, azithromycin reduced the parasite
number. Further, in bone marrow macrophages, infected with
amastigotes and treated with different concentrations, also there was a
dose dependent significant reduction of parasites. When BALB/cBYS
rats were inoculated with the same microorganism, an inflammatory
reaction on the site of inoculation and a decrease of parasite number
following azithromycin administration were observed
(KROLEWIECKI et al., 2002).
An open trial in an area, endemic for infections due to Leishmania
(Viannia) braziliensis, was carried out to evaluate azithromycin efficacy
in cutaneous leishmaniasis. Twenty-four patients received this drug in
different doses and time and a whole scarring of lesions was observed
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in 85% of them (PRATA et al., 2003). Most recently, a report on three
old chronic cardiopathy patients with mucosal involvement that
hindered classical treatment, azithromycin dose was given with good
results (SILVA-VERGARA et al., 2004).
The aim of this work was to evaluate the azithromycin efficacy in
cutaneous leishmaniasis in Manaus, AM, Brazil, where infections due
to Leishmania (Viannia) guyanensis are predominant.
POPULATION AND METHODS
This trial was carried out during 2002 in Manaus, Amazonas, Brazil
where Leishmania transmission actively has occurred during several
decades due to the enlargement of agricultural borders, new human
settlement in the road-side and irregular urbanization, where native
forest was previously found.
The Fundação de Medicina Tropical do Amazonas, a State
Leishmaniasis Reference Center, receive most patients of the city to
clinical evaluation, treatment and follow-up. Among them, 41 patients
were selected for this trial. The inclusion criteria were: skin lesions
with less than 12 weeks evolution-time; positive imprint to Leishmania
sp.; age ranged from 14 to 70, both genders and no treatment history
for the last three months. Patients with difficulty to attend to monthly
clinical assessment; mucosal or diffuse involvement, fever, macrolide
allergy, cardiac, hepatic or renal diseases, vasculopathies, diabetes
mellitus, AIDS, use of corticosteroids or immunosuppressive drugs or
engaged in another trial, were excluded.
All patients underwent a Montenegro intradermal test using UFMG®
antigen, following the classical procedure described. Analysis of AST,
ALT, blood urea nitrogen, serum creatinine, glycemia and other tests
when indicated were carried out.
At the first day patients received 10 capsules of 500 mg of
azithromycin and they were oriented to ingest a single-daily oral dose
of 500 mg of azithromycin after meals for ten days and were asked for
returning after 25 days for follow-up. If the patient had improved or
his lesion remained unchanged, another cycle of azithromycim as above
described was then offered. In case of worsening of lesions or on
patient’s demand, a daily intramuscular 20 mg/kg dose of antimony
during 20 days was prescribed. The cure criteria was defined as whole
lesion reepitelization and clinical failure was considered if on 25th day,
the lesion had worsened, or lack of response on day 55, or worsening
on day 85.
The study was approved by the Ethic Committee of the Fundação
de Medicina Tropical do Amazonas and written informed consent was
obtained from each patient.
RESULTS
From April to June 2002, 41 patients with cutaneous leishmaniasis
were recruited. From these, 31 (75.6%) were male, median age 30.2,
twenty five (61%) had two or more ulcers, that in 27 (70.7%) presented
classic aspect and supraumbilically localized. Most patients had history
of four or less weeks of lesion evolution and a Montenegro intradermal
test evaluated after 48 hours was positive in 32 (78%) cases.
On 25th day, two patients refused to continue in the study and two
did not come back for clinical evaluation. The other 37 individuals
were divided in three subgroups according to their clinical outcome
and further management.
Group I, nine (24.3%) patients received two cycles of azithromycin.
On day 25, six (16.2) improved nearly 80% and three (8.1) 60%. Only
three (8.1%) of them presented cure of lesions on 55th, 85th and 115th
days. The other six patients, despite their clinical improvement, did
not come back to final assessment.
Group II, 12 (32.4%) patients received two azithromycin cycles.
Although in nine of them the lesion remained inaltered on day 25, they
decided to stay in the trial until day 55 when all switched to antimony
therapy. One of them developed mucosal lesions during the follow-up.
Group III, 16 (43.2%) patients received one azithromycin cycle.
On day 25 were considered as therapeutic failure, because their lesions
had worsened. Therefore, all of then received antimony therapy. Among
them, one patient did not come for evaluation; other developed mucosal
lesions and one third claimed of intolerance to azithromycin (Table 1).
In general, azithromycin was well tolerated and accepted by most
patients, although, 24 (35%) of them referred symptoms such as:
diarrhea, headache and nausea, occurring in seven (18.9%), six (16.2%)
and four (10.8%) respectively, but these factors were not sufficiently
to stop the treatment, except for one of them.
DISCUSSION
New therapeutic alternatives to treat leishmaniasis have been tested
to find a cheap, safe, effective, well tolerated and orally administered.
Table 1
Evaluation of azithromycin therapy in 41 patients with cutaneous leishmaniasis in Manaus, AM, Brazil
Day N AZM10 days N AZMCure N Improving No change Worsening Lost
0 41 41 - - - - -
25 37 21 - 12 9 16* 4
55 21 - 1 10 - 10** -
85 9 - 2 1 - - 6
115 3 - 3 - - - -
N: Number of patients; AZM: Azithromycin; * switched to antimony on day 25; ** switched to antimony on day 55 (including two patients that were improving).
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Ketoconazol, fluconazol, itraconazol, nifurtimox, dapsone and
allopurinol, among other trials, showed variable efficacy depending
on clinical picture and the Leishmania sp. involved (MARSDEN, 1985;
GRIMALDI Jr. et al., 1989; ALRAJHI et al. 2002). Preliminary
experimental and clinical reports have appointed azithromycin as a
potential drug (PRATA et al. 2003; SILVA-VERGARA et al. 2004).
For this reason, it was evaluated in patients with cutaneous
leishmaniasis presumed to be caused by L. (Viannia) guyanensis in
Manaus.
From 41 patients recruited, 37 performed at least two clinical
evaluations, 16 (43%) switched to antimony on day 25 because of
clinical worsening and only 21 (66.7%) completed two cycles of
azithromycin. Of these, 12 received treatment with pentavalent
antimonial on day 55. The analysis for the intention-treatment response
rate was considered in eight (22%) and three (7.3%) of them presented
whole clinical cure. Despite their good clinical evolution, six patients
did not return for final assessment and can not be considered cured.
These results are lower than those reported for antimony (30-40%) or
pentamidine (100%) in Manaus (ROMERO et al., 2001; TALHARI et
al., 1985).
Among patients that worsened during treatment, two developed
mucosal lesions whose main etiological agent in Brazil is L. (Viannia)
braziliensis. However its prevalence is very low compared with L.
(Viannia) guyanensis (97.3%) that occasionally causes mucosal
involvement (MARSDEN, 1985; LLANOS-CUENTAS et al., 1984;
ROMERO et al. 2001).
Yet, leishmania culture was performed in all patients but
contamination prevented species identification. Despite these results,
the great number of parasites observed on the imprints and its high
prevalence reported in Manaus, suggest that cutaneous lesions of these
patients was caused by Leishmania (Viannia) guyanensis.
How azithromycin can act on Leishmania sp. is still unknown and
some authors have suggested that it can stimulate phagocytosis,
chemotaxis and cytotoxicity. Besides, it would act as immune stimulator
(IANARO et al., 2000; XU et al., 1996). During the follow-up, patients
with good clinical response presented an early and fast improvement
of lesions appearance, followed by a very slow scarring process, what
might suggest a leishmaniostatic effect of this drug.
At present, there is not evidence of ideal dose and treatment time
with azithromycin in cutaneous leishmaniasis but preliminary clinical
observations suggest that this medicament must be given for several
weeks and other cycles may be repeated if necessary. The scheme
proposed in this trial aimed to follow a classical treatment time of 20
days with antimony for this clinical picture and this can or not be
divided in two cycles of 10 days with interval from 10 to 15 days
between them (PRATA et al., 2003; SILVA-VERGARA et al., 2004).
Most patients reported mild adverse effects related to the medicament
but all except one underwent full treatment, confirming its good
tolerance and safety in practice.
Several operational difficulties to accomplish follow-up, hindered
the evaluation of more patients in this place. However a cure rate of
7% substantially differs from results with classical medicaments and
clearly suggests a very low efficacy of azithromycin to treat
leishmaniasis in a place where the main etiologic agent is Leishmania
(Viannia) guyanensis.
RESUMO
Azitromicina para tratamento de leishmaniose cutânea em
Manaus, AM, Brasil
Para avaliar a eficácia da azitromicina na leishmaniose cutânea,
foi realizado ensaio clínico em Manaus, Amazonas, onde o agente
etiológico predominante é a Leishmania (Viannia) guyanensis. Incluídos
41 pacientes com lesões de menos de 12 semanas, sem história de
tratamento específico nos últimos três meses e com esfregaço positivo
para Leishmania sp. Destes, 31 (75,6%) eram masculinos, idade média
30,2 anos. Todos receberam azitromicina 500 mg em dose única oral,
diária, por 10 dias. No dia 25º, 16 (39%) pioraram e receberam
antimonial pentavalente via intramuscular por 20 dias e, 21 (61%) que
apresentaram melhora da lesão ou esta permanecia inalterada no 25º dia,
receberam outro ciclo de 10 dias de azitromicina e foram acompanhados
mensalmente. Destes, nove (21,9%) apresentaram piora das lesões na
avaliação do dia 55 e iniciaram tratamento com antimonial neste dia.
Dos 12 que permaneceram no estudo, porque tinham melhorado
clinicamente, três optaram por tratamento com antimonial pentavalente
no 55º dia e três apresentaram reepitelização completa das lesões nos
dias 55º, 65º e 115º. Seis pacientes não retornaram para avaliação final.
Análise por tentativa de tratamento foi 22% e cura confirmada em três
(7,3%) casos. Estes resultados mostraram que azitromicina tem baixa
eficácia para tratar leishmaniose em área onde a Leishmania (Viannia)
guyanensis é o agente etiológico predominante.
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